Results 151 to 160 of about 14,439 (224)

Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? [PDF]

open access: yesInt J Clin Pharm
Burton E   +7 more
europepmc   +1 more source

Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars. [PDF]

open access: yesJ Manag Care Spec Pharm
Mendelsohn AB   +5 more
europepmc   +1 more source

Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population. [PDF]

open access: yesJ Pharm Technol
DelPrete S   +6 more
europepmc   +1 more source

Biosimilars in pemphigus vulgaris

open access: yesIndian Journal of Dermatology, 2014
Sharmila Patil   +3 more
openaire   +3 more sources

The devolution of biosimilars regulations

open access: yes
After two decades of experience with biosimilars, physicochemical and in vitro biological comparison with their reference products appear sufficient to guarantee clinical safety and efficacy. Hence, the regulation of biosimilars has become redundant, and
Doevendans, Erik   +4 more
core  

Home - About - Disclaimer - Privacy